Literature DB >> 7778844

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.

R H Haas1, F Nasirian, K Nakano, D Ward, M Pay, R Hill, C W Shults.   

Abstract

Following the discovery of inhibition of electron transport complex 1 by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces a parkinsonian syndrome in humans, monkeys, and mice, several laboratories have reported abnormalities of complex I and other electron transport complexes (ETCs) in various tissues from patients with Parkinson's disease (PD). Criticism of the significance of these findings in the etiology of PD has centered on whether drug treatments or the debilitation of the disease process itself produced the low ETC activities. We present results from a blinded study of platelet mitochondrial ETC activities in 18 early untreated PD patients and 18 age- and sex-matched controls and in 13 spousal controls. Lower complex I activity in platelet mitochondria of PD patients was seen in early untreated disease and thus cannot be due to debilitation or drug therapy. Home environmental factors seem an unlikely explanation for the reduced complex I activity in PD patients but have not been excluded. Complex II/III activity was also reduced by 20% in PD compared with age-/sex-matched controls. The low complex I and II/III activities in platelet mitochondria appear to be related to the etiology of PD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778844     DOI: 10.1002/ana.410370604

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  119 in total

Review 1.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

3.  [Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122].

Authors:  Th Müller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

4.  Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Joanne Markham; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

Review 5.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

6.  Complex I deficiency in Parkinson's disease frontal cortex.

Authors:  W Davis Parker; Janice K Parks; Russell H Swerdlow
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

Review 7.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 10.  Parkinson's disease and mitochondrial complex I: a perspective on the Ndi1 therapy.

Authors:  Mathieu Marella; Byoung Boo Seo; Takao Yagi; Akemi Matsuno-Yagi
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.